Export

Daclatasvir
Essential medicine status
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.4. Antihepatitis medicines 6.4.4.2. Medicines for hepatitis C 6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
ATC codes: J05AP07
Indication
Chronic hepatitis C ICD11 code: 1E91.1
INN
Daclatasvir
Medicine type
Chemical agent
List type
Core pangenotypic when used in combination with sofosbuvir.
Formulations
Oral > Solid: 30 mg tablet (as hydrochloride) ; 60 mg tablet (as hydrochloride)
EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Daclatasvir
DrugBank
Daclatasvir
Summary of evidence and Expert Committee recommendations
The listing for daclatasvir was qualified by a note indicating that it is pangenotypic when used in combination with sofosbuvir. Pangenotypic direct acting antivirals are considered therapeutically equivalent for the purposes of selection and procurement at national level.